According to an editorial, despite these impressive results and recent approval by FDA for use of subcutaneously tocilizumab in patients with giant-cell arteritis, additional studies are needed before it can be recommended for all patients with as long-term effect of tocilizumab cannot be determined in 1 year. It notes that although tocilizumab was much more effective than prednisone alone, only approximately 50% of the patients treated with tocilizumab had prednisone-free remission. It suggests that perhaps blocking other cytokines or cells (such as T cells) or interrupting multiple pathways will be more effective. It adds that although the current trial showed fewer serious side effects with tocilizumab than with placebo, the drug carries black-box warnings about the risk of opportunistic infection. For the time being, the commentator suggests that he will reserve tocilizumab for patients who are at high risk for serious side effects from prednisone and for patients who have repeated flares that are not manageable with low doses of prednisone.